Clinical Trials Browser

Phase 1/2 × Leukemia, B-Cell × Interleukin-2 × Clear all

NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell